SCHEMBL4259136

SCHEMBL4259136

COC(=O)c1sc(C(=O)C(C)C)cc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.49
MAPT P10636 7/20 0.49
NPC1 O15118 3/20 0.49
CASP3 P42574 2/20 0.49
RAB9A P51151 2/20 0.49
SENP8 Q96LD8 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
IKBKB O14920 1/20 0.49
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 5/20 0.40
HPGD P15428 5/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
GLA P06280 3/20 0.40
GAA P10253 3/20 0.40
ATM Q13315 2/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.39
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239031 0.86 KDM4E (0.54) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL12523092 0.84 KDM4E (0.53) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL4776291 0.83 IKBKB (0.40) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL4774303 0.83 ALDH1A1 (0.38) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL4774305 0.83 ALDH1A1 (0.38) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL9400256 0.79 CISD2 (0.51) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL3249150 0.76 KDM4E (0.51) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL166726 0.75 MAPT (0.54) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL4176316 0.74 KDM4E (0.44) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL4261811 0.74 RAF1 (0.39) KDM4EMAPTALDH1A1HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-03-26 US disclosed
CN-101370501-A Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI AVENTIS (FR) 2009-02-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MCHR1, MPI, TPMT KDM4E 414/4885MAPT 4471/4885NPC1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.